Strategic partnerships X-Chem has a track record of expanding collaborations with major players (Orion Pharma, Evotec, Mitokinin) and continues to broaden early-stage discovery engagement, signaling growing potential for multi-year, integrated discovery programs with partners seeking end-to-end DEL-enabled services.

End-to-end capacity With involvement across screen-to-hit, hit-to-lead, lead optimization, and candidate identification, X-Chem offers a seamless, full-lifecycle drug discovery solution that appeals to pharma and biotech teams looking to consolidate vendors and accelerate timelines.

AI and DEL leverage The combination of DNA-encoded library technology and ArtemisAI positions X-Chem as a tech-forward partner for AI/ML-driven target exploration, opening opportunities with companies prioritizing computationally guided small molecule discovery.

Validated track record A strong success rate in identifying functional hits, ~100 programs licensed, and multiple clinical candidates since 2021 provides risk reduction messaging for potential customers evaluating partner quality and pipeline momentum.

Industry alignment Recent collaboration activity across diverse biotech sub-sectors, including antiviral programs and Huntington's disease initiatives, indicates flexibility to tailor programs to high-priority targets, enabling cross-therapy BD pitches and co-development discussions.